drugset / Trial / NCT06606067

Duloxetine to Prevent Chronic Postsurgical Pain After Inguinal Hernia Repair in Patients at High Risk

NCT06606067

Phase 3 Active not recruiting 294 enrolled Parc de Salut Mar Carlos III Health Institute · collab
RandomizedParallel-groupDouble-blindPrevention

Summary

The clinical trial will be conducted in 14 Spanish hospitals. It is estimated, based on our previous studies, that 2855 patients scheduled for elective inguinal hernia surgery will have to be assessed to detect patients with ≥ 27% level of risk for Chronic Post-Surgical Pain (CPSP). These high-risk patients will be randomized to 2 treatment groups: one will receive duloxetine for 2 weeks prior to surgery and 1 week after surgery (intervention group) and the other the placebo (control group) during the same periods. The primary outcome will be a ≥ 50% decrease in the CPSP incidence in the intervention group compared to the placebo group, 4 months after surgery.

Timeline

Start
2024-09-03
Primary completion
2026-07-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Duloxetine Small molecule 30 mg

Indications